|
The
aim of the study was to assess the efficacy of amlodipine (“Norvasc”,
Pfizer, USA) in treatment of essential hypertension with concomitant
coronary artery disease. 40 male patients with mild-moderate hypertension
( WHO) and stable angina pectoris were allocated to receive 5, then10 mg
of amlodipine during 8 weeks in open label study. Hypotensive effect was
assessed by office BP measurements and 24-hour ambulatory monitoring (ABPM),
ischemic threshold was evaluated by stress-test (bicycle ergometry) and
24-hour ECG (Holter) monitoring.
Conclusions: The hypotensive effect of drug was dose-related,
target BP was achieved in 88,5% of patients, ABPM relieved significant
(p<0.001) decrease in mean , diurnal and nocturnal BP, BP variability
and early morning rise of BP, HR and BP circadian rhythm was not altered.
Therapy significanly increases (p<0.01) total exercise duration, time
to angina onset, time to 1 mm ST-segment duration during stress-test,
total number and duration of transient ischemic episodes assessed with
Holter monitoring were decreased by 50%. The drug was well-tolerated.
|
|
1.
WHO/ISH
Recommendations for treating High Blood Pressure. J Hypert
1999;17:151-183.
2.
Nayler
G. Amlodipine. An Overview. Clinical Drug Investigator 1997, Vol13, Suppl
1.
3.
Goldschagen
N, Selrev A, Cohn K: Stress tests as indicators of presence and severity
of coronary artery disease . Ann Int Med 1985, 277, 1976
4.
Laragh
GH, Brenner BM. Hypertension: pathophysiology, diagnosis and management.
New York; 1990: 637-648
5.
Palatini
P, Mormorino P, Sperti G. Hypertension and related target organ damage
evaluated by causal and average 24-hour monitoring. V-th International
Symposium on Ambulatory BP Monitoring. Padova-CLEUP, 1986: 241-5
6.
Waeber
e, Brunner H. Ambulatory pressure monitoring. New York, Raven Press, 1994,
47-60.
7.
Kario
k, Matsuo T, Kobayashi H et al. Noctural fall of BP and silent
cerebrovascular damage. Hyperternsion, 1996; 27:130-135.
8.
Pickering
T, James G. Determinants and consequences of the diurnal rhythm of blood
pressure. Am J Hypert 1993, Suppl 6: 166S-169S
9.
Sylvestry
f and St. John Sutton MG. Sustained released CA in cardiovascular disease:
pharmacology and current theurapeutic use.
10.
Task
Force of European Society of Cardiology. Society of Pacing and
Electrophysiology. Heart rate variability – clinical use.
11.
Petretta
M, Morgano G, Arrichiello P et al. Calcium antagonists in the therapy of
stable exercise angina: evaluation of its efficacy in ergometry tests. Am
J Cardiol, 1990: 518-25.
12.
Barry
J, CambellS etal. Circadian variation of transient myocardial ischemia in
patients with CAD. Circulation 1987: 75, 395-400.
13.
Benhorin
J, Moriel M, Gavish A et al. Usefulness of severity of myocardial ischemia
on exercise testing in predicting the severity of myocardial ischemia
during dauly activities. Am J Cardiol 1991, 168: 176-180.
14.
Amlodipine/Atenolol
in Silent Ischemic Study (CASIS) Investigators. Effects of aAmlodipine,
Atenolol and Their Combination on Myocardial Ischemia
During Exercise and Ambulatory Monitoring. Eur Heart J, 1998,
Suppl2.
15.
Rocco
MB, Nabel EG, CambellS et al. Prognostic importance of myocardial ischemia
detected by ambulatory monitoring in patients with stable angina.
Circulation, 1998; 78:877-884.
16.
Deedwania
PC, Carbajal EV. Silent ischemia during daily life is an independent
predictor of mortality in stable angina. Circulation 1990, 81:
748-756.
17.
Pepne CJ, Cohn PF, Deedwania PC, Gibson AS. Effect of treatment on outcome
in patients with ischemia during daily life: ASIST study. Circulation,
1996, 90; 762-768.
|